Treatment of patients with high-risk neuroblastoma using a humanized monoclonal antibody

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Despite the use of multimodal therapy in patients with high-risk neuroblastoma (NB), the prognosis in high-risk patients remains unfavorable. Immunotherapy with monoclonal antibodies (mAb) in the post-consolidation period of treatment of high-risk NB has marked significant progress in improving the prognosis for patients who have achieved a good response to first-line therapy. Currently, the US Food and Drug Administration has approved three mAb drugs for the treatment of patients with high-risk NB: dinutuximab (Ch14.18), dinutuximab beta (Ch14.18/CHO), and naxitamab (Hu3F8). This publication is devoted to a review of the clinical use of the humanized mAb Hu3F8, the efficacy of which has been demonstrated in clinical trials.

This publication has 23 references indexed in Scilit: